Glaukos Corporation Reports 30% Revenue Growth to $124.1 Million in Q2 2025

Glaukos Corporation reported significant financial performance improvements in its latest quarterly filing, with net sales reaching $124.1 million for the three months ended June 30, 2025, a 30% increase from $95.7 million in the same period last year. For the first half of 2025, the company generated $230.8 million in net sales, up 27% from $181.3 million in the prior year. The gross profit margin also improved, rising to 78% from 76% year-over-year. Despite these gains, Glaukos recorded a net loss of $19.7 million for the second quarter, a notable reduction from a loss of $50.5 million in the same quarter of 2024.

The company attributed its revenue growth primarily to increased sales of its iDose TR product, which has gained traction in the market. U.S. sales of glaucoma products surged by 45% to $72.3 million, while international sales rose by 20% to $31.3 million, driven by strong performance in key markets such as Japan and France. However, sales of the iStent family of products faced challenges due to restrictions imposed by local coverage determinations from Medicare Administrative Contractors (MACs).

In terms of strategic developments, Glaukos completed the acquisition of Mobius Therapeutics on May 16, 2025, for $12.4 million, which is expected to enhance its product portfolio in glaucoma treatment. The company also invested $16.6 million in a new property adjacent to its headquarters in Aliso Viejo, California, aimed at supporting future expansion. As of June 30, 2025, Glaukos had cash and cash equivalents totaling $100.8 million, down from $169.6 million at the end of 2024, alongside short-term investments of $174 million.

Operationally, Glaukos reported an increase in accounts receivable, which rose to $83 million, reflecting the growing sales volume, particularly of iDose TR, which has extended payment terms. The company’s employee headcount has also increased as it expands its commercial infrastructure to support growth. Looking ahead, Glaukos anticipates continued challenges related to supply chain disruptions and inflation, which may impact gross margins and product availability. The company is optimistic about the potential for increased utilization of iDose TR as reimbursement processes stabilize and plans to launch new products, including Epioxa, in the coming years.